Skip to main content
. 2016 Feb 3;7:10521. doi: 10.1038/ncomms10521

Figure 5. Effects of miR-103 on chemokine expression in ECs and monocyte adhesion.

Figure 5

(a) Chemokine mRNA expression in HAECs treated with Dicer-specific LNA-GapmeRs or control LNA-GapmeRs with (right) or without (left) miR-103-mimic treatment (n=4–6 per group). (b,c) Quantitative RT–PCR analyses of miR-103 (b) and chemokine mRNA (c) expression levels in HAECs (n=5–6 per group) treated with LNA-inhibitors of miR-103 or non-targeting LNA-oligonucleotides. (d) ELISA of CXCL1 protein expression in HAEC lysates (n=3–4 per group) with and without miR-103 inhibition. (e) Flow chamber assays to determine monocyte adhesion to HAECs treated with LNA-inhibitors of miR-103 or control oligonucleotides (n=3 per group). (f,g) The expression of miR-103 (f) or chemokine mRNAs (g) in HAECs treated with miR-103-specific or negative control mimics (n=3–4 per group). (h) Adhesion of monocytes to HAECs treated with miR-103-mimics or control oligonucleotides under flow conditions. Monocytic cells were pretreated with or without an antibody to block CXCR2 or non-targeting control IgG (n=3 per group). The data are represented as the mean±s.e.m. of the indicated number (n) of repeats. *P<0.05, **P<0.01 and ***P<0.001 by Student's t-test (b–d) and one-way analysis of variance (a,e).